Abstracts tiveness ratio (ICER) was calculated as cost ($CDN) per QALY gained. QALYs were derived from the health assessment questionnaire (HAQ) scores collected prospectively on patients. RESULTS: With the effectiveness-based analysis, the QALYs gained during the 12-month monitoring period were estimated to be 0.45 and 0.35, for the treatment and control groups respectively. The resulting ICER was $167,282 (CDN) per QALY. Using boot-strapping techniques and cost-effectiveness acceptability curves the 95% confidence interval (CI) for the ICER was $119,500 to $285,000 per QALY. For the efficacy-based analysis, the incremental QALYs gained were 0.56 and 0.35, for the treatment and control groups respectively. This resulted in a substantially lower ICER, $81,213 per QALY [95% CI = 66,500, 103,430]. CONCLUSION: Depending on the data used for the analysis, the resulting ICER was very different ($167,282 versus $81,213 per QALY). This study highlights some the potential concerns with using RCT data for estimating cost-effectiveness. These results are consistent with, and help to explain, the difference in cost-effectiveness reported in 2 previous modeling studies, one based on efficacy data and the other based on effectiveness data.
tiveness ratio (ICER) was calculated as cost ($CDN) per QALY gained. QALYs were derived from the health assessment questionnaire (HAQ) scores collected prospectively on patients. RESULTS: With the effectiveness-based analysis, the QALYs gained during the 12-month monitoring period were estimated to be 0.45 and 0.35, for the treatment and control groups respectively. The resulting ICER was $167,282 (CDN) per QALY. Using boot-strapping techniques and cost-effectiveness acceptability curves the 95% confidence interval (CI) for the ICER was $119,500 to $285,000 per QALY. For the efficacy-based analysis, the incremental QALYs gained were 0.56 and 0.35, for the treatment and control groups respectively. This resulted in a substantially lower ICER, $81, 213 per QALY [95% CI = 66, 500, 103, 430] . CONCLUSION: Depending on the data used for the analysis, the resulting ICER was very different ($167, 282 versus $81, 213 per QALY) . This study highlights some the potential concerns with using RCT data for estimating cost-effectiveness. These results are consistent with, and help to explain, the difference in cost-effectiveness reported in 2 previous modeling studies, one based on efficacy data and the other based on effectiveness data. Several cost-effectiveness studies have shown that the innovative highly effective, but costly new biological therapies are within acceptable ranges in rheumatoid arthritis (RA). The transferability of international results is limited. Country-specific data, standardised methodologies are needed to study the adaptability of cost-effectiveness models and to obtain comparable economic evaluations. OBJECTIVES: The aim of our study was to assess the burden and costs of the Hungarian RA population for the purpose of further cost-effectiveness studies and modeling of biological therapies. METHODS: A cross sectional questionnaire survey was performed in 2004 in 6 rheumatology centres focusing on clinical characteristics, resource utilisation, EQ-5D and HAQ were also used. A systematic search was performed in the National Health Insurance Found database. RESULTS: A total of 255 consecutive RA out-patients involved, mean age 55.3 years, females 86%, disease duration 9.12 years, HAQ 1.38, DAS28 5.09, EQ-5D 0.46, DMARD therapy 87.9%, steroids 48%. Progression in HAQ correlates with utility (EQ-5D: 0.78-0.19). Costs: 55 % indirect costs (early retirement: 49%), direct medical costs 28% (hospital admissions 11%); direct nonmedical costs 17% (informal care givers 15%). In 2000, 117,338 out-patient visits occurred with RA diagnosis. A total of 5089 patients were hospitalized because of RA (63528 bed-days, mean duration 12.4 days), leading to about €1,340,000 consumption of reimbursement. CONCLUSIONS: Our study investigated Hungarian RA patients' characteristics, health-care consumption and burden of illness. The questionnaire survey included patients with characteristics of target patients for biological therapy. Health status utility decrease and costs increase consistently with functional disability progression, early retirement and informal care have major impact. Biological therapies are not reimbursed yet in Hungary though arthritis centres network and guidelines has been established. Our study offers standardized data for economic analysis focusing on the adaptability of international costeffectiveness studies and models of biological therapies in the Hungarian context.
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BURDEN OF ILLNESS, COSTS AND OUTCOMES OF RHEUMATOID ARTHRITIS IN HUNGARY
PAR18 PATIENT COMPLIANCE IN THE TREATMENT OF RHEUMATOID ARTHRITIS WITH BIOLOGIC DMARDS AND PREDICTING FACTORS: A LITERATURE REVIEW
Schmidt E 1 , Kielhorn A 2 1 Analytica International GmbH, Loerrach, Germany; 2 F. Hoffmann-La Roche Ltd, Basel, Switzerland OBJECTIVES: Poor compliance/adherence has been shown to be one of the leading causes for sub-optimal clinical benefit. Overall adherence in chronic diseases averages 50%, in rheumatoid arthritis (RA) 50-70%. A comprehensive literature survey was performed to explore the field of compliance with biologic DMARDs (bDMARDs), in particular regarding patient satisfaction with different regimens, and to assess predicting factors of compliance in RA treatment in general. METHODS: Relevant articles were identified through search in a DIMDI Superbase (10 databases). Three search concepts were combined: compliance in RA treatment 1) with bDMARDS, 2) with focus on different administration modes 3) in general (reviews >1990). Additionally, bibliographies and the Internet were reviewed. Juvenile arthritis was excluded. RESULTS: Focus and approach of the identified publications are highly varied. However, there are only a few reliable data. So far, published compliance data with bDMARDs are quasi limited to the first two approved drugs. Compliance rates of bDMARDs tend to be higher than those for RA in general, calculated on basis of prescription refills (Olszynski 2004 , Harley 2003 . Patients' preferences were evaluated in three surveys. Two compared twice-weekly subcutaneous (SC) injections with bi-monthly intravenous (IV) infusions, showing a tendency in preference towards bi-monthly IV infusion. Factors influencing compliance in RA treatment are older age, female sex, decreased disability, and satisfactory contacts with health care professionals (Viller 1999). Patient education showed positive (Viller 1999 , Hill 2001 or no effects (Brus 1998). Less frequent dosing regimens (Claxton 2001) resulted in better compliance, also bi-monthly IV infusion versus twice-weekly SC injection (Jarry 2002). CONCLUSIONS: Compliance with bDMARDs appears to be higher than with traditional RA treatment. Patients' preference regarding administration mode tends towards IV infusion but needs further investigation, distinguishing between kind and frequency of administration. Due to the poor data compliance with bDMARDS needs further qualitative and quantitative investigation.
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CRITERIA-BASED INTERPRETATION OF SF-36 IMPROVEMENTS FROM ADALIMUMAB PLUS METHOTREXATE (MTX) COMBINATION THERAPY VS. MTX ALONE IN EARLY RHEUMATOID ARTHRITIS (RA)
Cifaldi M 1 , Sterz R 2 , Dietz B 2 , Chmiel J 1 , Spencer-Green GT 3 1 Abbott Laboratories, Abbott Park, IL, USA; 2 Abbott GmbH and Co KG, Ludwigshafen, Germany; 3 Abbott Laboratories, Parsippany, NJ, USA OBJECTIVES: To assess the ability of adalimumab + MTX to improve health-related quality of life (HRQOL) in early RA and interpret the results. METHODS: PREMIER was a 2-year study of MTX-naïve, adult patients with early RA (<3 years) who received: adalimumab 40 mg every other week (eow) + MTX; adalimumab 40 mg eow; or MTX monotherapy. The Short Form 36 (SF-36) was used to assess 8 domains of HRQOL at baseline, and after 12, 26, 42, 52, 76, and 104 weeks of therapy (higher scores indicate improvement). Scores for 4 physical and 4 mental health concepts were aggregated into Physical Component Summary (PCS) and Mental Component Summary (MCS) scores. A minimum clinically important difference (MCID) is 2.5-5.0 for PCS and MCS. Criteria-based interpretation of the PCS evaluated relationships between clinically and socially meaningful variables. RESULTS: Baseline scores for the 799 patients were comparable between all 3 groups, and post-baseline results were comparable for the 2 monotherapy groups. Mean baseline PCS for the adalimumab + MTX (n = 256) and MTX monotherapy (n = 247) groups were 31.7 and 32.2. Mean PCS for the combination therapy group at Week 12 had improved to 42.2 vs. 38.2 for the MTX group. The 4.5 difference in mean change from baseline was clinically meaningful and sustained through 2 years (5.1) (p < 0.0001). Based on criteriabased interpretation of the SF-36, differences in PCS scores between the 2 groups indicate patients on MTX alone had an increased likelihood of using more health resources and not being able to work. CONCLUSIONS: Adalimumab + MTX were superior to MTX alone in providing significant and clinically meaningful improvements in HRQOL in early RA. Significantly lower PCS at 2 years in the MTX group may mean patients on MTX alone have greater health care utilization and substantially greater job loss than patients on combination therapy.
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EFFECTS OF LONG-TERM ADALIMUMAB THERAPY ON HEALTH UTILITY AND FATIGUE IN PATIENTS WITH LONG-STANDING, SEVERE RHEUMATOID ARTHRITIS (RA)-RESULTS FROM A 3-YEAR FOLLOW-UP STUDY
Mittendorf T 1 , Sterz R 2 ,Von der Schulenburg J 1 , Kupper H 2 , Cifaldi M 3 , Dietz B 2 1 University of Hannover, Hannover, Germany; 2 Abbott GmbH and Co KG, Ludwigshafen, Germany; 3 Abbott Laboratories, Abbott Park, IL, USA OBJECTIVES: To investigate the ability of adalimumab therapy to provide simultaneous, sustained long-term improvement in two important patient-reported outcomes (health utility and fatigue) in patients with severe RA who had failed at least one DMARD. METHODS: The Health Utilities Index Mark 3 (HUI3) and Fatigue (FACIT-F, validated in RA) were simultaneously measured in a health economics companion trial to an adalimumab pivotal study (DE011). For the first 26 weeks patients were followed under double-blind, randomized conditions before rolling over into a long-term, open-label extension (OLE) (n = 99). A subset of patients receiving adalimumab 40 mg every other week was evaluated for up to 170 weeks. The HUI3 scale is 0-1, with "1" denoting perfect health and "0" denoting death. FACIT-F scores range from 0-52, with higher scores representing less fatigue. Changes in HUI3 of ≥0.03 and FACIT-F of ≥4 are considered clinically meaningful. RESULTS: Baseline patient characteristics were: female, 80%; age, 53 years; duration of disease, 10 years; TJC (0-68), 34; SJC (0-66), 21; HAQ score, 1.9; C-reactive protein (mg/L), 54; number of previous DMARDs: 4 (all mean values except % female). RA patients' baseline utility and fatigue scores were comparable (vs. placebo) and approximately one-third of the population norm. At week 26, mean changes from baseline in adalimumab-treated patients were 0.18 for HUI3, and 8.54 for FACIT-F (both p < 0.001 vs. baseline). These improvements were sustained through-out week 170. CONCLUSIONS: Adalimumab provided clinically important, simultaneous improvements in health utility and fatigue in patients with severe, active RA who had failed at least one DMARD. These improvements were sustained over the 3year observation period.
ASTHMA PAS1
COMPARISON OF TREATMENT WITH BUDESONIDE/FORMOTEROL (BUD/FM) PLUS BUD/FM PRN AS SINGLE INHALER TREATMENT VERSUS REGULAR BUD AND FM PLUS FM PRN AS MONOPRODUCTS IN PATIENTS WITH ASTHMA IN GREECE
Papageorgiou M 1 , Loukides S 2 , Gaga M 3 , Zervas L 3 , Christodoulopoulou A 1 , Georgatou N 3 1 AstraZeneca SA, Athens, Athens, Greece; 2 401 Military Hospital, Athens, Athens, Greece; 3 Sotiria Hospital, Athens, Athens, Greece OBJECTIVE: To compare the efficacy of regular treatment with BUD/FM plus BUD/FM prn versus regular treatment with budesonide (BUD) and formoterol (FM) plus FM prn in the treatment of asthmatic patients in Greece. METHODS: Moderate asthmatic (mean FEV1 76% pred.) patients were recruited from 14 centers in Greece to participate in an open-label, randomized prospective clinical trial. The duration of the study was seven months with four scheduled visits: baseline, first month, third month and seventh month. Patients were randomized in 2 groups: Group A: BUD/FM 160/4.5 ìg bid plus BUD/FM prn and Group B: BUD 200 ìg and FM 9 ìg bid plus FM prn. Outcome measures included lung function, number of exacerbations and relief inhalations, symptom control using the Asthma Control Questionnaire (ACQ) and quality of life using the Asthma Quality of Life Questionnaire (AQLQ). In addition, the use of health services and side effects were recorded. RESULTS: A total of 133 patients were recruited, 68 in Group A, and 65 in Group B. Both groups showed a significant improvement in ACQ at the end of the study (p < 0.0001). Relief inhalations were significantly less in Group A (p < 0.0001) during the last study period, between 3rd and 7th month. No statistically significant differences were found in the other outcome measures. CONCLU-SIONS: BUD/FM therapy plus BUD/FM as needed demonstrated similar effectiveness in asthma control and quality of life compared to treatment with BUD and FM plus FM as needed. Since fewer relief inhalations were recorded in Group A, BUD/FM plus BUD/FM prn treatment seems preferable for patients with asthma.
PAS2 FLUTICASONE PROPIONATE/SALMETEROL COMBINATION IMPROVES HEALTH OUTCOMES AND QUALITY OF LIFE IN CHILDREN WITH POORLY CONTROLLED ASTHMA IN IRELAND
Hill P 1 , Hughes J 2 , Grant D 3 , Sawyer W 3 , Reeves P 3 1 Blackpool Health Centre, Cork City, Cork, Ireland; 2 GlaxoSmithKline Ireland, Dublin, Ireland; 3 Fourth Hurdle Consulting Ltd, London, UK OBJECTIVE: To investigate whether salmeterol/fluticasone propionate 50/100 mcg (SFC) improves quality of life, physical functioning and asthma symptoms in children with uncontrolled asthma in primary care. METHODS: A prospective open label study of children seven to twelve years old attending their GP with uncontrolled asthma. SFC bd was taken for 16 weeks (w) from enrolment. Peak expiratory flow rate (PEFR) was measured at baseline, w4 and w16, when the Paediatric Asthma Quality of Life Questionnaire (PAQLQ) was completed. Patient diaries
